#ASCO 2020

Active Cancer, Recent Chemo Linked to Higher COVID-19 Death Rates

First-line treatment with immunotherapy and a chemotherapy regimen extended progression-free survival by 35%.

The program also greatly improved patients’ satisfaction with their hospital stays.

Keytruda plus chemotherapy reduced the risk of disease progression or death by 35% compared with chemotherapy alone in certain people.

Here are a few highlights related to melanoma from the first-ever Virtual AACR Annual Meeting and Virtual ASCO Annual Meeting.

New research explores how to lower the risk of heart disease in childhood cancer survivors.

The use of the algorithm helped increase these kids’ progression-free survival.

David Fajgenbaum, MD, crowdsourced treatment for the lymphoma-like Castleman disease. His research may help find new drugs for COVID-19.

“The cancer care community urgently needs data on the effects of COVID-19, specifically in patients with cancer."

Starting palliative interventions at the onset of hospitalization for chemotherapy greatly improves quality of life.

Other benefits include better cancer care planning for people over 70.